First Patient Dosed in Phase 1 Study with Novel Anti-cancer Immunotherapy Q702

Dortmund, Germany, Jan 27th, 2021 - The LDC's long-term strategic partner Qurient has dosed the first patient in a Phase 1 clinical study of Q702 involving patients with advanced solid tumors at multiple sites in the US.

Q702 is an orally available triple kinase inhibitor targeting Axl, Mer and CSF1R. It was discovered at the Max Planck Institute of Biochemistry and further developed at the LDC, before it was licensed to Qurient for further optimization and preclinical and clinical development. The candidate was shown to boost immune cells in the tumor microenvironment and to raise tumor visibility to the immune system. It may provide new options to patients for whom available therapies are ineffective.

For the original press releases, see:

Qurient's latest press release from January 26th, 2021
Qurient's and LDC's press release on IND approval from May 2020

# # #

>> Contact
PR Lead Discovery Center
+49 (0)231-97 42 70 00
pr@lead-discovery.de

# # #

About Qurient
Qurient is a clinical-stage biopharmaceutical company listed in Korea Exchange (KRX 115180). Qurient mainly focuses on development of novel therapeutics from discovery to human proof of concept stages through virtual R&D project management platform. Qurient currently has three programs in clinical development: Q301, a topical leukotriene inhibitor for atopic dermatitis, completed Phase 2b study; telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for tuberculosis, completed Phase 2 study; and Q702, entering Phase 1/2 study. Qurient recently nominated Q901, a selective CDK7 inhibitor, as a preclinical candidate for solid tumors, which is expected to enter the clinic in 2021. For more info, please visit www.qurient.com.

About LDC
Lead Discovery Center GmbH was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The Lead Discovery Center takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals. In close collaboration with high-profile partners from academia and industry, the Lead Discovery Center is building a strong and growing portfolio of small molecule leads with exceptional medical and commercial potential. The Lead Discovery Center sustains a long-term partnership with the Max Planck Society, KHAN-I GmbH & Co.KG and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, e.g. In addition,

LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation. Further information at: www.lead-discovery.de.

About Max Planck Innovation

Max Planck Innovation (MI) is responsible for the technology transfer of the Max Planck Society and, as such, the link between industry and basic research. With an interdisciplinary team, MI advises and supports scientists at Max Planck Institutes in evaluating their inventions, filing patents and founding companies. MI offers industry unique access to the innovations of the Max Planck Institutes. Thus, MI performs an important task: the transfer of basic research results into products that contribute to economic and social progress. Further information at: www.max-planck-innovation.com.

Press Release

>> Our Mailing-Address:
Lead Discovery Center GmbH
Otto-Hahn-Straße 15
Dortmund 44227
Deutschland